BCLI — Brainstorm Cell Therapeutics Inc.

Summary of BCLI Q2 2025 Earnings Call

1. Key Financial Results and Metrics

• Net Loss: Approximately $2.9 million, or $0.34 per share, compared to a net loss of $2.5 million, or $0.60 per share, in Q2 2024.
• R&D Expenditures: $1.1 million for the quarter, up from $0.9 million in the same period last year.
• General and Administrative Expenses: Approximately $1.4 million, a decrease from $2.1 million in Q2 2024.
• Cash Position: Approximately $1 million in cash, cash equivalents, and restricted cash as of June 30, 2025.

2. Strategic Updates and Business Highlights

• Phase IIIb Trial (ENDURANCE): The company is preparing to initiate this pivotal trial for NurOwn in early-stage ALS patients, having received FDA clearance under a Special Protocol Assessment (SPA).
• Manufacturing Partnerships: Secured a partnership with Minaris Advanced Therapies for U.S.-based manufacturing, complementing an existing collaboration with Pluri Inc. in Israel.
• Citizens Petition: A coalition of ALS patients filed a petition with the FDA requesting a reevaluation of NurOwn data, which Brainstorm supports as it could open new regulatory pathways.

3. Forward Guidance and Outlook

• Trial Initiation: The company is ready to begin patient enrollment for the Phase IIIb trial, pending the resolution of funding challenges.
• Regulatory Strategy: A positive outcome from the Citizens petition could facilitate funding opportunities and accelerate the trial process.
• Long-term Vision: Brainstorm aims to leverage NurOwn's potential beyond ALS, exploring applications in other neurodegenerative diseases.

4. Bad News, Challenges, or Points of Concern

• NASDAQ Compliance: The company has transitioned from NASDAQ to OTCQB due to noncompliance with minimum shareholder equity requirements, which poses challenges for future funding and visibility.
• Funding Difficulties: The inability to secure a significant funding round has delayed the initiation of the Phase IIIb trial and impacted the submission for nondilutive funding.
• Regulatory Uncertainty: The filing of the Citizens petition has created a "wait-and-see" approach among investors, complicating the company's funding efforts.

5. Notable Q&A Insights

• Trial Timeline: Management indicated that the initiation of the Phase IIIb trial is contingent on securing funding, which has been complicated by the Citizens petition.
• Nondilutive Funding: The company faced delays in applying for nondilutive funding due to timing issues and insufficient co-funding at the time of application.
• Regulatory Pathways: The FDA's response to the Citizens petition could significantly impact the company’s ability to secure funding and proceed with the trial.
• Survival Data: Management emphasized the importance of long-term survival data from the expanded access program, which could support regulatory discussions and the potential for accelerated approval.

Overall, while Brainstorm Cell Therapeutics is making progress in its clinical initiatives and has strategic partnerships in place, it faces significant challenges related to funding and regulatory compliance that could impact its operations and growth trajectory.